Paper9699893
Lipoprotein desialylation simultaneously enhances the cell cholesterol uptake and impairs the reverse cholesterol transport system: in vitro evidences utilizing neuraminidase-treated lipoproteins and mouse peritoneal macrophages.
Harada LM and 3 others. Atherosclerosis, 1998. Cited by 20 papers, by iCite.
Cite this record
ConductScience Library. Lipoprotein desialylation simultaneously enhances the cell cholesterol uptake and impairs the reverse cholesterol transport system: in vitro evidences utilizing neuraminidase-treated lipoproteins and mouse peritoneal macrophages. Papers, record 9699893. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9699893
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Lipoprotein desialylation simultaneously enhances the cell cholesterol uptake and impairs the reverse cholesterol transport system: in vitro evidences utilizing neuraminidase-treated lipoproteins and mouse peritoneal macrophages.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cholesterol | Major topic |
| Glycoproteins | Major topic |
| Lipoproteins | Major topic |
| Macrophages, Peritoneal | Major topic |
| Neuraminidase | Major topic |
| Animals | |
| Biological Transport | |
| Carrier Proteins | |
| Cells, Cultured | |
| Cholesterol Ester Transfer Proteins | |
| Cholesterol Esters | |
| Humans | |
| Mice | |
| Phosphatidylcholine-Sterol O-Acyltransferase | |
| Sialic Acids |
Source PubMed
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 36157440 | Lipoprotein sialylation in atherosclerosis: Lessons from mice. | Front Endocrinol (Lausanne) | 2022 | https://conductscience.org/library/papers/36157440 | PubMed |
| 34234868 | Oxidized-Desialylated Low-Density Lipoprotein Inhibits the Antitumor Functions of Lymphokine Activated Killer Cells. | J Cancer | 2021 | https://conductscience.org/library/papers/34234868 | PubMed |
| 34070542 | Proatherogenic Sialidases and Desialylated Lipoproteins: 35 Years of Research and Current State from Bench to Bedside. | Biomedicines | 2021 | https://conductscience.org/library/papers/34070542 | PubMed |
| 31330845 | The Atherogenic Role of Circulating Modified Lipids in Atherosclerosis. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/31330845 | PubMed |
| 25050779 | Modified low density lipoprotein and lipoprotein-containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular disease. | Int J Mol Sci | 2014 | https://conductscience.org/library/papers/25050779 | PubMed |
| 17069350 | Diminished macrophage cholesterol removal rate by the altered HDL metabolism in the Nagase analbuminemic rat. | Lipids | 2006 | https://conductscience.org/library/papers/17069350 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CETP | 1071 | PubTator's text mining | https://conductscience.org/library/genes/1071 | NCBI Gene |
| LCAT | 3931 | PubTator's text mining | https://conductscience.org/library/genes/3931 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9699893
GET https://conductscience.org/api/papers/v1/9699893/authors